More Stories

Informist, Thursday, Aug. 6, 2026

 

Please click here to read all liners published on this story

--CONTEXT: Comments by Biocon management in post-earnings analyst call 
--Biocon: Strengthened regional supply network through global mfg footprint 
--Biocon: Expanding commercial footprint in France, Portugal, Slovenia, Spain 
--Biocon: Generic liraglutide is contributing across multiple markets, even 
-- Biocon: GLP-1 portfolio remains a key growth driver for co 
-- Biocon:To improve utilisation, product scale-up to strengthen profitability 
-- Biocon: See no material increase in competitive intensity in generics 
-- Biocon: Contribution from new launches picking up, not fully reflected in Q1 
-- Biocon: Expects new launches to scale up in subsequent quarters 
-- Biocon: Expects Aflibercept launch to be a key growth driver in FY27 
-- Biocon: Plans to add more products to its oncology portfolio 
-- Biocon: API-to-formulations mix stood at 60:40 in Q1 
-- Biocon:Biosimilars inventory days fell to around 280 290 days from 400 days 
-- Biocon: See no immediate impact from Trump's tariff remarks 
--Biocon: Will leverage existing mfg footprint, partnerships for US market 
 

 

By Gunjan Rajput and Avishek Rakshit

 

KOLKATA/NEW DELHI – Biocon Ltd. expects recently launched products, including generic liraglutide and biosimilar aflibercept, to drive growth and support margin expansion in the financial year 2026-27 as their contribution scales up over the coming quarters, backed by operating leverage and cost optimisation, company executives said in a post-earnings analyst call on Thursday. 

 

Management said generic liraglutide, launched across multiple markets including the US, is currently contributing only in single digits to the generics business, indicating that the full benefit of the launch is yet to be reflected in earnings. "The new launches are expected to scale up, even in generics, in the subsequent quarters. The work on OPEX (Operating Expenditure)and the thinking on productivity remains very strong," said a company official in the analyst call.  
 

The company said that there has been no material increase in competitive intensity in the generics market. The glucagon-like peptide-1 portfolio continues to be an important growth driver, with generic liraglutide contributing across several markets. It added that investments in peptides, fermentation, and manufacturing capabilities should support stronger profitability as utilisation improves and newer products scale up. 

 

"As utilization levels improve and newer products continue to scale up, we remain focused on further strengthening profitability generating stronger cash flows and enhancing returns on capital," a company official added. 

 

On the biosimilars business, the management identified the recently launched aflibercept as a key growth driver for FY27, noting that the ophthalmology product has entered the US market ahead of several competitors and should gain momentum through the second half of the fiscal year. "Now, we should have a good, you know, straight out of the gates, a good start to this, which will build up towards the second half of the year," a company official in the analyst call. The company also said it plans to add more products in its oncology portfolio.
 

For the June quarter, Biocon reported a consolidated net profit of INR 1.41 billion on revenues of INR 43.36 billion.

 

 

The company said biosimilars inventory days have already declined to about 280-290 days from over 400 earlier, reflecting better working capital efficiency, while inventory built during the June quarter is aimed at supporting an expected scale-up in the second half. 

 

Biocon also said it was expanding its commercial footprint through partnerships in France, Portugal, Slovenia, and Spain, while strengthening regional supply networks through its global manufacturing footprint and local partnerships. On potential US tariffs, the management said it saw no immediate impact, noting that generics and biosimilars remain exempt under current US law and any change would require legislation. 

 

"I don't believe that we will be increasing our capex in establishing new facilities or capacities in the US. We will look at it through partnerships if required. And we already have some of our own manufacturing facilities which we will obviously utilise," a company official said. 

The company detailed its earnings on Wednesday. At IST 1227, shares of the company traded at INR 439.50 on the National Stock Exchange, up 3.4%.   End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.